TheodoreSunkiHongMD

Radiation Oncology • Boston, MA

Gastrointestinal Cancer

Professor, Radiation Oncology-Massachusetts General Hospital, Harvard Medical School

Join to view full profile

Dr. Hong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hong's full profile

Already have an account?

Office
100 Blossom St
Radiation Oncology
Boston, MA 02114
Phone+1 617-726-6050

Fax+1 617-726-3603

Summary

Dr. Theodore Hong is a radiation oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital, Emerson Hospital, and Newton-Wellesley Hospital. He received his medical degree from University of Connecticut School of Medicine and has been in practice 17 years. He specializes in gastrointestinal cancer.

Education & Training

University of Wisconsin Hospitals and ClinicsResidency, Radiation Oncology, 2001 - 2005
University of Wisconsin Hospitals and ClinicsInternship, Internal Medicine, 2000 - 2001
Uconn School Of MedicineClass of 2000

Certifications & Licensure

MA State Medical License 2005 - 2025
ME State Medical License 2020 - 2025
NH State Medical License 2021 - 2025
RI State Medical License 2020 - 2022
WI State Medical License 2004 - 2009
American Board of Radiology Radiation Oncology

Clinical Trials

Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 1, Phase 2
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases Start of enrollment: 2003 Jun 01
Completed
Not Applicable
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma Start of enrollment: 2009 Aug 01
Completed
Not Applicable
Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Individualized Stereotactic Body Radiotherapy of Liver Metastases Start of enrollment: 2010 Jun 01
Completed
Not Applicable
Midostaurin (PKC412) for Locally Advanced Rectal Cancer Start of enrollment: 2011 Aug 01
Completed
Phase 1
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer Start of enrollment: 2011 Dec 01
Active, not recruiting
Phase 2
FOLFIRINOX + RT for Pancreatic Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 2
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer Start of enrollment: 2013 Jul 01
Active, not recruiting
Phase 2
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer Start of enrollment: 2014 Sep 29
Terminated
Phase 3
A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma Start of enrollment: 2014 Oct 01
Terminated
Not Applicable
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Start of enrollment: 2017 May 10
Recruiting
Phase 2
Preoperative Radiotherapy and E7046 in Rectum Cancer Start of enrollment: 2017 May 17
Completed
Phase 1
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers Start of enrollment: 2017 Oct 24
Active, not recruiting
Phase 1
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Start of enrollment: 2018 May 14
Recruiting
Phase 2
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer Start of enrollment: 2018 Aug 10
Active, not recruiting
Phase 2
Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement Start of enrollment: 2019 Mar 19
Recruiting
Not Applicable
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer Start of enrollment: 2019 Dec 31
Withdrawn
Join now to see all

Publications & Presentations

PubMed

Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma.
Stephanie O Dudzinski, Neil B Newman, Jeff McIntyre, Reena Engineer, Nina N Sanford
The Lancet. Gastroenterology & Hepatology. 2025-04-01
Utilizing Patient Input in Rectal Cancer Trial Design.
Janet Alvarez, Wini Zambare, Manju George, Reese Garcia, Phuong Gallagher
Journal of the National Cancer Institute. 2025-03-19
3 citations
NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy.
Nina N Sanford, Amol K Narang, Todd A Aguilera, Michael F Bassetti, Michael D Chuong
International Journal of Radiation Oncology, Biology, Physics. 2025-03-15

Journal Articles

Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer
Harvey J Mamon, Paul L Nguyen, Theodore S Hong, Aparna Parikh, Jennifer Y Wo, Rinaa S Punglia, Cristina Ferrone, Ryan D Nipp, Annals of Surgical Oncology

Lectures

A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Against - Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ...
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Pre/Post-Operative Chemo-Radiation
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Advances in Cancer Management for the Surgeon
Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 10/31/2012
Join now to see all

Press Mentions

Understanding Stage 4 Esophageal CancerNovember 15th, 2024
IntraOp® Announces First Patient Enrolled in PACER Trial for Pancreatic CancerMay 9th, 2019
Failure Is Not an OptionSeptember 17th, 2018
Join now to see all

Grant Support

Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy.MASSACHUSETTS GENERAL HOSPITAL2021–2026
Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy.MASSACHUSETTS GENERAL HOSPITAL2021–2026